Neoproct Kombinationsförpackning (Fluocortolone Pivalate, Anhydrous Lidocaine Hydrochloride)

Neoproct Kombinationsförpackning combines a corticosteroid and a local anesthetic to address inflammatory and painful conditions of the rectal area.

• Hemorrhoidal disease: reduces swelling, itching and discomfort associated with internal and external hemorrhoids.
• Anal fissure: alleviates pain and promotes healing of fissure‑related inflammation.
• Proctitis: diminishes mucosal inflammation and associated symptoms in ulcerative or infectious proctitis.

• Fluocortolone pivalate binds to intracellular glucocorticoid receptors, modulating gene transcription to suppress pro‑inflammatory cytokines, reduce leukocyte infiltration, and stabilize cellular membranes. Lidocaine hydrochloride blocks voltage‑gated sodium channels in peripheral nerve fibers, preventing depolarization and interrupting pain signal transmission. The combined actions provide localized anti‑inflammatory and analgesic effects when applied rectally.

Rectal administration of Neoproct Kombinationsförpackning may be associated with local and systemic adverse reactions.

Common Side Effects

• Mild burning sensation: transient feeling of heat at the application site.
• Local itching: occasional pruritus in the rectal mucosa.
• Minor irritation: redness or mild inflammation of the surrounding tissue.
• Dryness: temporary dryness of the rectal lining.

Serious or Rare Side Effects

• Allergic reaction: rash, swelling, or anaphylaxis requiring immediate medical attention.
• Systemic corticosteroid effects: adrenal suppression, hyperglycemia, or hypertension with prolonged use.
• Severe rectal bleeding: unexpected heavy bleeding indicating mucosal ulceration.

Before using Neoproct Kombinationsförpackning, consider the following precautions to ensure safe and effective therapy.

• Hypersensitivity: avoid if known allergy to fluocortolone, lidocaine or any excipients.
• Infection: do not use in the presence of untreated bacterial, viral or fungal rectal infections.
• Immunosuppression: use with caution in patients receiving systemic immunosuppressive therapy.
• Pregnancy and lactation: safety has not been established; consult a healthcare professional before use.
• Duration of therapy: limit use to the shortest period necessary to control symptoms to reduce systemic absorption risk.
• Store at room temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Neoproct Kombinationsförpackning may interact with other medicines; awareness of significant interactions helps prevent adverse outcomes.

Major Interactions (Avoid)

• Systemic corticosteroids: concurrent use may increase risk of systemic glucocorticoid side effects.
• Anticoagulants (e.g., warfarin): may enhance bleeding tendency if rectal mucosa is irritated.
• CYP3A4 inhibitors (e.g., ketoconazole): can raise local fluocortolone levels, potentially augmenting effects.

Moderate Interactions (Monitor Closely)

• Other topical anesthetics: additive local numbness may occur.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): monitor for increased gastrointestinal irritation.
• Immunomodulators (e.g., methotrexate): observe for enhanced immunosuppression.
• St. John’s wort: may affect corticosteroid metabolism.